Myriad Genetics Total Liabilities

Myriad Genetics (MYGN) currently reports a total liabilities of $340M as of June 2026. That compares with $290M in the prior-year period — up 15.8% year over year. Use the charts on this page to explore Myriad Genetics's total liabilities history and peer comparisons.

Myriad Genetics's total liabilities increased from $290M to $340M — a 15.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Myriad Genetics reported $340M in total liabilities as of June 2026. That compares with $290M in the prior-year period — up 15.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $340M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Myriad Genetics, and consider following MYGN for alerts when major investors trade the stock.

Myriad Genetics is classified in the Healthcare sector. On total liabilities, it currently shows $340M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MYGN with unrelated industries.